• Epsium posted a net loss of US$ 1.5 million for fiscal year ended Dec. 31, 2025, swinging from profit a year earlier.
• Revenue dropped 59.11% to US$ 5.12 million on depressed local economic activity, intensified competition, and lower wholesale pricing.
• Operating loss widened to US$ 1.5 million as general and administrative expenses climbed 77.92% to US$ 2.12 million on higher public-company costs and M&A-related consulting fees.
• Business updates included a March 2025 Nasdaq IPO raising US$ 4.24 million in net proceeds, followed by US$ 667,500 in net proceeds from full exercise of the over-allotment option.
• Strategy shifted toward partnerships tied to Macau’s push as a “Performing Arts Capital,” with Epsium also signing an exclusive agent agreement to pursue biotech-related intellectual property for wine vintage applications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Epsium Enterprise Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-049163), on April 29, 2026, and is solely responsible for the information contained therein.